OTTAWA, Ontario--(BUSINESS WIRE)--
BIOTECanada announced earlier today Therapure Biopharma Inc. (Therapure)
has been named recipient of a Gold Leaf Award recognizing an outstanding
early stage health company. Therapure is being recognized for the
potential of their highly innovative drug discovery pipeline as well as
for their unique biomanufacturing capabilities. Therapure is a contract
development and manufacturing organization launched in 2008 and has
rapidly grown to more than 120 employees. Therapure specializes in
producing sophisticated biologics at its 130,000 square foot, cGMP
bio-manufacturing facility in Mississauga, Ontario.
"Therapure has distinguished themselves among their peers with
incredible technology innovation," commented Brad Thompson, Chair
BIOTECanada. "Their scientific dedication is one we can all be proud.
Therapure is providing paramount service to partners across Canada and
internationally."
"Therapure is privileged to receive this award and honoured to be
recognized by our industry peers. Our growth is based on a strong
foundation of protein manufacturing expertise as well as a rich pipeline
of drug development candidates. We look forward to continued growth and
expansion opportunities," said Nick Green, President and CEO of
Therapure.
Join us as we celebrate industry leadership during the BIO International
Convention at the Boston Convention & Exhibition Center. The Gold Leaf
Awards ceremony will take place at the Canada Café (booth number 735)
June 19, 2012 in Boston, MA at 4pm.
ABOUT THERAPURE
Since its launch into the Contract Development and Manufacturing
Organization (CDMO) space in 2008, Therapure has achieved impressive
growth including the execution of more than 30 service contracts with a
broad spectrum of Canadian and international customers. In addition to
its CDMO services, Therapure also has a portfolio of internal drug
development programs focused on liver cancer, hepatitis C and
chemotherapy-induced anemia. All of the products are pre-commercial with
the lead program scheduled to begin Phase 1 in 2012. Therapure's drug
discovery pipeline is built on a deep knowledge and understanding of
hematology. Therapure's products are protected by an extensive portfolio
of issued patents in the fields of protein drug conjugation and
hematopoietic stem cells. Therapure is a key contributor in the creation
of a centre of excellence in biotech manufacturing for Canada. With its
unique services and pipeline products, Therapure represents a very
significant opportunity to become a leading provider of CDMO services to
the biological industry as well as a developing drug candidates targeted
towards major unmet medical needs.
